Join to View Full Profile
1515 Holcombe BlvdHouston, TX 77030
Phone+1 713-792-6161
Fax+1 713-563-5067
Dr. Thomas is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Texas Health Sciences CenterM.S., Clinical Research, 2004 - 2008
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2002 - 2005
Temple University HospitalResidency, Internal Medicine, 1999 - 2002
Boston University School of MedicineClass of 1999
Barrow Neurological Institute at St Joseph's Hospital and Medical CenterResidency, Neurology
Certifications & Licensure
FL State Medical License 2021 - Present
GA State Medical License 2022 - 2028
TN State Medical License 2022 - 2028
MS State Medical License 2022 - 2027
TX State Medical License 2002 - 2027
WA State Medical License 2022 - 2027
AL State Medical License 2022 - 2026
American Board of Internal Medicine Medical Oncology- Join now to see all
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification ClinicStation, UT MD Anderson Cancer Center, 2013, 2015
Clinical Trials
- Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia Start of enrollment: 2006 Aug 02
- Pomalidomide in Treating Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia Start of enrollment: 2010 Oct 06
- Vaccine Therapy in Treating Patients With Lymphoplasmacytic Lymphoma Start of enrollment: 2015 Feb 26
Publications & Presentations
PubMed
- Acalabrutinib in Waldenström macroglobulinemia yields durable responses with 5 years of follow-up.Roger G Owen, Helen McCarthy, Shirley D'Sa, Sheeba K Thomas, Olivier Tournilhac
Blood Advances. 2026-07-28 - Single Cell Analysis of the Tumor Microenvironment Landscape Across the Disease Spectrum of Multiple Myeloma.Minghao Dang, Luz Yurany Moreno Rueda, Maria Jose Acevedo Calado, Hima Bansal, David Alejandro Berrios Nolasco
Blood. 2026-07-07 - A Simplified Frailty Score Predicts Outcomes in Newly Diagnosed Multiple Myeloma Patients Undergoing Upfront Autologous Hematopoietic Stem Cell Transplantation.Chelby Wakefield, Curtis Marcoux, Denái R Milton, Mark R Tanner, Qaiser Bashir
Transplantation and Cellular Therapy. 2026-07-06
Journal Articles
- Primary Plasma Cell Leukemia: Autologous Stem Cell Transplant in an Era of Novel Induction DrugsKrina Patel, Rohtesh Mehta, Donna M Weber, Sheeba K Thomas, Nina Shah, Hans C Lee, Elisabet E Manasanch, Muzaffar H Qazilbash, Qaiser Bashir, Simrit Parmar, Robert Z O..., Nature
- Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191Sheeba K Thomas, Robert Z Orlowski, Hans C Lee, Clinical Cancer Research
- Phase I Study of an Active Immunotherapy for Asymptomatic Phase Lymphoplasmacytic Lymphoma with DNA Vaccines Encoding Antigen-Chemokine Fusion: Study ProtocolSattva S Neelapu, D Lynne Smith, Vincent Y Lee, Larry W Kwak, Sheeba K Thomas, BioMed Central
Abstracts/Posters
- Outcomes of Lenalidomide Retreatment with Novel Triplet Regimens in Multiple Myeloma Patients Progressing on Lenalidomide-Based Maintenance Therapy: A Single Center Re...Sheeba K. Thomas, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Preliminary Safety and Anti-Tumor Activity of XmAb13676, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Non-HodgkinÍs Lymphoma and C...Sheeba K. Thomas, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- A Multicenter Phase II Single Arm Trial of Isatuximab in Patients with High Risk Smoldering Multiple Myeloma (HRSMM)Sheeba K. Thomas, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Lectures
- Phase I trial of a novel DNA vaccine in patients (pts) with smoldering Waldenstrom macroglobulinemia (sWM).2019 ASCO Annual Meeting - 6/1/2019
- Older Age As a Prognostic Factor for Overall Survival for Multiple Myeloma Patients Undergoing Upfront Autologous Hematopoietic Stem Cell Transplantation2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Outcome of Autologous Stem Cell Transplantation in Waldenström's Macroglobulinemia2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
